

Author's Accepted Manuscript

Stem cell transplantation for immunoglobulin light chain (AL) amyloidosis

Taimur Sher, Morie A. Gertz



PII: S0147-0272(16)30206-9

DOI: <http://dx.doi.org/10.1016/j.currproblcancer.2017.03.001>

Reference: YMCN337

To appear in: *Current Problems in Cancer*

Cite this article as: Taimur Sher and Morie A. Gertz, Stem cell transplantation for immunoglobulin light chain (AL) amyloidosis, *Current Problems in Cancer*, <http://dx.doi.org/10.1016/j.currproblcancer.2017.03.001>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Stem cell transplantation for immunoglobulin light chain (AL) amyloidosis.

Taimur Sher MD; Morie A Gertz MD, MACP.

Taimur Sher MD (corresponding author)

Mayo Clinic Florida

Morie A Gertz MD, MACP

Mayo Clinic Rochester

Introduction:

Immunoglobulin light chain amyloidosis (AL) is a plasma cell dyscrasia characterized by extracellular deposition of amyloidogenic light chain fragments that result in progressive organ dysfunction. With a median survival of 12-17 months AL is a fatal disease[1] as death results from rapid clinical deterioration due to the involvement of heart, kidneys, liver and the gastrointestinal tract. Treatment of AL involves the use of antineoplastic therapy aiming at eradicating the underlying transformed plasma cells, the source of amyloidogenic light chains, and providing organ directed supportive care. Anti-plasma cell therapy in AL has evolved along the lines of multiple myeloma and involves standard dose therapy or high dose myeloablative therapy as part of autologous stem cell transplantation (SCT). In this review we focus on the evolution of the role of SCT in AL, the unique challenges it poses in the management of AL patients and its evolving role in the era of new treatment modalities.

Download English Version:

<https://daneshyari.com/en/article/5664237>

Download Persian Version:

<https://daneshyari.com/article/5664237>

[Daneshyari.com](https://daneshyari.com)